Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGKA | P23743 | 1/20 | 0.69 |
| ▸ | PAM | P19021 | 2/20 | 0.62 |
| ▸ | TSHR | P16473 | 2/20 | 0.58 |
| ▸ | MAPT | P10636 | 1/20 | 0.58 |
| ▸ | LMNA | P02545 | 4/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.56 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | PRKCA | P17252 | 1/20 | 0.51 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.51 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.51 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.51 |
| ▸ | CES2 | O00748 | 3/20 | 0.50 |
| ▸ | CES1 | P23141 | 3/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29366771 | 1.00 | DGKA (0.69) | DGKAPAMTSHRMAPTLMNA | |
| SCHEMBL10901771 | 1.00 | DGKA (0.69) | DGKAPAMTSHRMAPTLMNA | |
| SCHEMBL2857061 | 1.00 | DGKA (0.69) | DGKAPAMTSHRMAPTLMNA | |
| SCHEMBL28699910 | 1.00 | DGKA (0.69) | DGKAPAMTSHRMAPTLMNA | |
| SCHEMBL355177 | 1.00 | DGKA (0.69) | DGKAPAMTSHRMAPTLMNA | |
| SCHEMBL6266491 | 1.00 | DGKA (0.69) | DGKAPAMTSHRMAPTLMNA | |
| SCHEMBL10414846 | 1.00 | DGKA (0.69) | DGKAPAMTSHRMAPTLMNA | |
| SCHEMBL353797 | 1.00 | DGKA (0.69) | DGKAPAMTSHRMAPTLMNA | |
| SCHEMBL356145 | 1.00 | DGKA (0.69) | DGKAPAMTSHRMAPTLMNA | |
| Heptanoic Acid Chloromethyl Ester SCHEMBL697729 | 1.00 | DGKA (0.69) | DGKAPAMTSHRMAPTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 115 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122070276-A | Prodrugs of xanomeline, prodrugs of trospium chloride and methods of using the same | 人类生物科学股份有限公司 | 2026-05-19 | — | — | CN | disclosed |
| EP-4705289-A1 | PRODRUGS OF XANOMELINE, PRODRUGS OF TROSPIUM AND METHODS OF USE THEREOF | Terran Biosciences Inc. (US) | 2026-03-11 | — | — | EP | disclosed |
| EP-4707284-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | Otsuka Pharmaceutical Co., Ltd. (JP) | 2026-03-11 | — | — | EP | disclosed |
| US-12570605-B2 | Indole compounds, and preparation methods, and uses thereof | SHENZHEN 01 LIFE SCIENCE AND TECHNOLOGY CO., LTD. (CN) | 2026-03-10 | — | — | US | disclosed |
| US-12545672-B2 | Antibiotic compounds, methods of manufacturing the same, pharmaceutical compositions containing the same and uses thereof | DEBIOPHARM INTERNATIONAL S.A. (CH) | 2026-02-10 | — | — | US | disclosed |
| US-20250197397-A1 | ORGANIC COMPOUNDS | INTRA-CELLULAR THERAPIES, INC. (US) | 2025-06-19 | — | — | US | disclosed |
| US-12329747-B2 | Use of lipophilic beta-lactam antibiotics and carboxylate esters for the treatment of bacterial infections within citrus and other plant species | Board of Regents of the Nevada System of Higher Education on behalf of Nevada State College (US) | 2025-06-17 | — | — | US | disclosed |
| US-12240850-B2 | Pharmaceutical compositions comprising 4-((6bR, 10aS)-3-methyl-2,3,6b,9,10, 10a-hexahydro-1H,7H-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalin-8-yl)-1-(4-fluorophenyl)butan-1-ol for treating central nervous system disorders | INTRA-CELLULAR THERAPIES, INC. (US) | 2025-03-04 | — | — | US | disclosed |
| WO-2024228399-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | 大塚製薬株式会社 | 2024-11-07 | — | — | WO | disclosed |
| EP-3880675-B1 | ANTIBIOTIC COMPOUNDS, METHODS OF MANUFACTURING THE SAME, PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AND USES THEREOF | DEBIOPHARM INT SA (CH) | 2024-11-06 | — | — | EP | disclosed |
| US-20110003828-A1 | PRODRUGS OF NH-ACIDIC COMPOUNDS | ALKERMES, INC. | 2011-01-06 | — | — | US | disclosed |
| EP-2212325-A2 | 2-ARYLMETHYLAZETIDINE-CARBAPENEM-3-CARBOXYLIC ACID ESTER DERIVATIVE OR ITS SALT, PROCESS FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | Kukje Pharm. Ind. Co., Ltd. (KR) | 2010-08-04 | — | — | EP | disclosed |
| WO-2009066917-A2 | 2-ARYLMETHYLAZETIDINE-CARBAPENEM-3-CARBOXYLIC ACID ESTER DERIVATIVE OR ITS SALT, PROCESS FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | KUKJE PHARM. IND. CO., LTD. (KR) | 2009-05-28 | — | — | WO | disclosed |
| CN-1155595-C | Substituted pyrroles as antiproliferative agents for the treatment of cancer | - | 2004-06-30 | — | — | CN | disclosed |
| CN-1378545-A | Substituted pyrroles as antiproliferative agents for treatment of cancer | HOFFMANN LA ROCHE (CH) | 2002-11-06 | — | — | CN | disclosed |
| EP-0808315-B1 | CARBAPENEM-3-CARBOXYLIC ACID ESTER DERIVATIVES | WYETH LEDERLE JAPAN LTD (JP) | 2001-04-04 | — | — | EP | disclosed |
| US-5886172-A | ORAL PRODRUG READILY ABSORPED IN THE DIGESTIVE TRACT AND HYDROLYZED; BIOAVAILABIITY; STRONG ANTIBACTERIAL ACTIVITY ESPECIALLY AGAINST STAPHYLOCOCCUS; STREPTOCOCCUS, KLEBSIELLA AND PROTEUS | LEDERLE (JAPAN) LTD. (JP) | 1999-03-23 | — | — | US | disclosed |
| EP-0808315-A1 | CARBAPENEM-3-CARBOXYLIC ACID ESTER DERIVATIVES | LEDERLE (JAPAN), Ltd. (JP) | 1997-11-26 | — | — | EP | disclosed |
| WO-1997021712-A1 | CARBAPENEM-3-CARBOXYLIC ACID ESTER DERIVATIVES | LEDERLE (JAPAN), LTD. (JP) | 1997-06-19 | — | — | WO | disclosed |
| US-4567034-A | Esters of diatrizoic acid as X-ray contrast agents | E. R. SQUIBB & SONS, INC. (US) | 1986-01-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12240850-B2 | Pharmaceutical compositions comprising 4-((6bR, 10aS)-3-methyl-2,3,6b,9,10, 10a-hexahydro-1H,7H-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalin-8-yl)-1-(4-fluorophenyl)butan-1-ol for treating central nervous system disorders | HTR2A, HTR2C, HTR1B | DGKA 3497/4885PAM 3693/4885TSHR 263/4885 |
| US-12329747-B2 | Use of lipophilic beta-lactam antibiotics and carboxylate esters for the treatment of bacterial infections within citrus and other plant species | LIPA, ENGASE, COASY | DGKA 1789/4885PAM 527/4885TSHR 4579/4885 |
| US-12545672-B2 | Antibiotic compounds, methods of manufacturing the same, pharmaceutical compositions containing the same and uses thereof | MRPL21, EMG1, RRS1 | DGKA 4724/4885PAM 397/4885TSHR 1787/4885 |
| US-20250197397-A1 | ORGANIC COMPOUNDS | HTR2A, HTR2C, TPH2 | DGKA 1480/4885PAM 2798/4885TSHR 384/4885 |
| US-20110003828-A1 | PRODRUGS OF NH-ACIDIC COMPOUNDS | SI, NAAA, NIT2 | DGKA 4304/4885PAM 74/4885TSHR 3738/4885 |
| US-12570605-B2 | Indole compounds, and preparation methods, and uses thereof | IDO2, IDO1, TPH2 | DGKA 2440/4885PAM 3927/4885TSHR 1333/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.